GlassScriptPhysician profile
Neelima Kunam
NPI 1114269685
$58,596.57
in general payments reported to CMS, 2019-2025
31 companies · $679 in 2025
The $679 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $573 · 2021: $8,558 · 2022: $21K · 2023: $19K · 2024: $8,557 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $2,930 · Travel and Lodging: $1,108 · Consulting Fee: $850 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,836.50 |
| Food and Beverage | $2,929.94 |
| Travel and Lodging | $1,107.90 |
| Consulting Fee | $850.00 |
| Education | $183.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $31,498.24 | 2021-2024 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $10,117.72 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $8,744.86 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $3,879.46 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $943.52 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $385.95 | 2020-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $383.86 | 2021-2024 | Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $352.45 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $287.84 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $283.55 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $270.22 | 2020-2022 | |
| Lundbeck LLC | $242.12 | 2020-2024 | Rexulti |
| Allergan, INC. | $200.34 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $133.22 | 2022-2024 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $132.96 | 2022-2023 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $123.83 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $92.43 | 2021-2024 | Fanapt, Hetlioz |
| Biogen, INC. | $85.00 | 2024 | Zurzuvae |
| Bausch Health US, LLC | $80.58 | 2020-2023 | Aplenzin |
| Axsome Therapeutics, INC. | $57.76 | 2023 | Auvelity |
| Adlon Therapeutics L.P. | $55.30 | 2020-2021 | |
| Medtronic, INC. | $54.05 | 2022 | |
| Eisai INC. | $29.97 | 2020-2021 | |
| Neuronetics, INC. | $29.05 | 2020 | |
| Tempus Ai, INC | $25.65 | 2024 | |
| Brainsway USA INC | $24.78 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.13 | 2023 | Spravato |
| Corium, LLC | $19.90 | 2022 | |
| Alfasigma USA, INC. | $13.12 | 2022 | |
| Merck Sharp & Dohme LLC | $12.72 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelima Kunam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.